Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5170012 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5171314 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL27628462 | 0.99 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL16707204 | 0.92 | PTGS2 (0.90) | PTGS2PTGS1 | |
| SCHEMBL19107464 | 0.92 | PTGS2 (0.90) | PTGS2PTGS1 | |
| SCHEMBL213531 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5168838 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5171166 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL27628322 | 0.88 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL213041 | 0.87 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330004-B | Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2023-11-17 | — | — | CN | claimed |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | ASKAT INC. (JP) | 2023-01-17 | — | — | US | claimed |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2022-05-12 | — | — | US | claimed |
| EP-3906232-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | AskAt Inc. (JP) | 2021-11-10 | — | — | EP | claimed |
| WO-2020153279-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2020-07-30 | — | — | WO | claimed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | claimed |
| EP-1778662-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | claimed |
| CN-1768050-A | Benzopyran compounds for the treatment of inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| WO-2006011045-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2006011047-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2006011052-A1 | METHOD FOR THE RACEMIZATION OF 2-TRIFLUORO-2H-CHROMENE-3-CARBOXYLIC ACIDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | claimed |
| US-20060016683-A1 | Photoracamization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | claimed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | claimed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | claimed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | claimed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | claimed |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | ASKAT INC. (JP) | 2023-01-17 | — | — | US | disclosed |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3906232-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | AskAt Inc. (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020153279-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2020-07-30 | — | — | WO | disclosed |
| EP-3509604-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | Trustees of Tufts College (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018187698-A2 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018049014-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049015-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PD-1 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049008-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049027-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| EP-3094333-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015109011-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1778662-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| CN-1768050-A | Benzopyran compounds for the treatment of inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006011045-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011047-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011052-A1 | METHOD FOR THE RACEMIZATION OF 2-TRIFLUORO-2H-CHROMENE-3-CARBOXYLIC ACIDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060016683-A1 | Photoracamization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| CN-1196692-C | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2005-04-13 | — | — | CN | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| CN-1515566-A | Substituted chromene derivative for curing inflammation | G.D. | 2004-07-28 | — | — | CN | disclosed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | disclosed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PTGS2 1336/4885PTGS1 901/4885 |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | PTGS2 3/4885PTGS1 6/4885 |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | UACA, SLC7A1, CDYL | PTGS2 3076/4885PTGS1 4536/4885 |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | UACA, SLC7A1, CDYL | PTGS2 3076/4885PTGS1 4536/4885 |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20060020023-A1 | Racemization method | STS, SQLE, HAO2 | PTGS2 1102/4885PTGS1 1630/4885 |
| US-20060016683-A1 | Photoracamization method | CYP3A43, CRY2, CRY1 | PTGS2 728/4885PTGS1 1526/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | PTGS2 3281/4885PTGS1 4145/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | PTGS2 4/4885PTGS1 7/4885 |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | CD274, ICOS, PDCD1 | PTGS2 3149/4885PTGS1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.